Roche reported strong mid‑stage results for its most advanced obesity program and moved the asset toward global phase 3 testing. One Roche report showed about an 18.3% placebo‑corrected weight loss in a nearly year‑long Phase 2 cohort after statistical adjustment; a separate briefing tied the dual GLP‑1/GIP receptor agonist to 22.5% weight loss at 48 weeks and confirmed plans to start Phase 3. Roche’s readouts validate the company’s decision to escalate the program and put it directly into competition with other next‑generation incretin therapies. The data give Roche a clear efficacy signal to support larger registrational trials and inform dose and comparator choices in Phase 3. For competitors and investors, the results emphasize that GIP/GLP‑1 combinations continue to deliver steep weight‑loss trajectories versus older agents. Clarification: GLP‑1 and GIP are incretin hormones; dual agonists engage both receptors to amplify appetite suppression and metabolic effects compared with single‑receptor drugs.